Uma Borate, MD
Along with biological factors such as age and disease characteristics, a new study has found that nonbiological factors including marital status, county-level income, and insurance status may also affect the chances of survival among young patients with acute myelogenous leukemia (AML).
Researchers at the University of Alabama at Birmingham (UAB) found that patients aged younger than 65 who were unmarried, lived in lower-income areas, and who were uninsured or Medicaid beneficiaries were at significantly higher risk of premature mortality.
“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” lead author Uma Borate, MD, assistant professor in the UAB Division of Hematology and Oncology, said in a statement.
In the study, which was published online in Cancer, the investigators analyzed a database of 5541 patients between the ages 19 and 64 who were diagnosed with AML between 2007 and 2011 and reported to the Surveillance, Epidemiology, and End Results program registry (SEER 18).
Nonbiological factors, including marital status, insurance status, county-level income, and education were assessed along with biological factors including disease subtype, gender, age, race, and ethnicity.
The median survival for the study population was 16 months, and on multivariate analysis, increased risk of death was associated with being a Medicaid beneficiary, uninsured, single, divorced, or living in a low-income county. Nonbiological factors also affected the risk of early (<2 months) and late mortality among patients who received chemotherapy.
AML will affect approximately 20,830 in 2015, and an estimated 10,460 Americans will die of the disease. While much is known about biological factors and their prognostic implications, this is the largest study to date that examines the effect of socioeconomic factors on outcomes of younger patients with AML.
“As physicians, we often emphasize more of the biology of the cancer, especially with the recent focus on personalized medicine,” author Luciano Jose Costa, MD, PhD, associate professor in the UAB Division of Hematology and Oncology, said in a statement. “But we need to pay the same attention to resources available to our patients, as this greatly impacts their chances to survive leukemia.”
The authors concluded that marital status, insurance status, and income should be integrated into outcome comparisons for younger patients with AML. Interventions are also needed to mitigate the impact of these factors on survival, the researchers noted.
“Taking from the results of this study, factors that have nothing to do with quality of care need to be accounted for when comparing predicted with actual outcomes—otherwise we will create a disincentive for hospitals and doctors to care for less privileged patients,” Borate said.
Borate UM, Mineishi S, Costa LJ. Nonbiological factors affecting survival in younger patients with acute myeloid leukemia [published online September14, 2015]. Cancer.
Social Factors Affect Survival in Young Leukemia Patients
A new study has found that nonbiological factors including marital status, county-level income, and insurance status may also affect the chances of survival among young patients with acute myelogenous leukemia (AML).
Uma Borate
Uma Borate, MD
Along with biological factors such as age and disease characteristics, a new study has found that nonbiological factors including marital status, county-level income, and insurance status may also affect the chances of survival among young patients with acute myelogenous leukemia (AML).
Researchers at the University of Alabama at Birmingham (UAB) found that patients aged younger than 65 who were unmarried, lived in lower-income areas, and who were uninsured or Medicaid beneficiaries were at significantly higher risk of premature mortality.
“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” lead author Uma Borate, MD, assistant professor in the UAB Division of Hematology and Oncology, said in a statement.
In the study, which was published online in Cancer, the investigators analyzed a database of 5541 patients between the ages 19 and 64 who were diagnosed with AML between 2007 and 2011 and reported to the Surveillance, Epidemiology, and End Results program registry (SEER 18).
Nonbiological factors, including marital status, insurance status, county-level income, and education were assessed along with biological factors including disease subtype, gender, age, race, and ethnicity.
The median survival for the study population was 16 months, and on multivariate analysis, increased risk of death was associated with being a Medicaid beneficiary, uninsured, single, divorced, or living in a low-income county. Nonbiological factors also affected the risk of early (<2 months) and late mortality among patients who received chemotherapy.
AML will affect approximately 20,830 in 2015, and an estimated 10,460 Americans will die of the disease. While much is known about biological factors and their prognostic implications, this is the largest study to date that examines the effect of socioeconomic factors on outcomes of younger patients with AML.
“As physicians, we often emphasize more of the biology of the cancer, especially with the recent focus on personalized medicine,” author Luciano Jose Costa, MD, PhD, associate professor in the UAB Division of Hematology and Oncology, said in a statement. “But we need to pay the same attention to resources available to our patients, as this greatly impacts their chances to survive leukemia.”
The authors concluded that marital status, insurance status, and income should be integrated into outcome comparisons for younger patients with AML. Interventions are also needed to mitigate the impact of these factors on survival, the researchers noted.
“Taking from the results of this study, factors that have nothing to do with quality of care need to be accounted for when comparing predicted with actual outcomes—otherwise we will create a disincentive for hospitals and doctors to care for less privileged patients,” Borate said.
Borate UM, Mineishi S, Costa LJ. Nonbiological factors affecting survival in younger patients with acute myeloid leukemia [published online September14, 2015]. Cancer.
Lower Rates of ICANS, CRS 2 Weeks After CAR T May Support Shorter Monitoring Period for DLBCL
The monitoring period after CAR T-cell therapy may be safe if shortened due to the lower incidence of ICANS and CRS 2 weeks after treatment in patients with DLBCL.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Adding brentuximab vedotin to lenalidomide/rituximab results in a stronger overall survival benefit compared with lenalidomide/rituximab alone in relapsed/refractory diffuse large B-cell lymphoma.
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.
Cilta-Cel Shows Promising OS Improvement in Lenalidomide-Refractory Multiple Myeloma
Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
Lower Rates of ICANS, CRS 2 Weeks After CAR T May Support Shorter Monitoring Period for DLBCL
The monitoring period after CAR T-cell therapy may be safe if shortened due to the lower incidence of ICANS and CRS 2 weeks after treatment in patients with DLBCL.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Adding brentuximab vedotin to lenalidomide/rituximab results in a stronger overall survival benefit compared with lenalidomide/rituximab alone in relapsed/refractory diffuse large B-cell lymphoma.
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.
Cilta-Cel Shows Promising OS Improvement in Lenalidomide-Refractory Multiple Myeloma
Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
Latest Conference Coverage
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Durvalumab Plus Chemo Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer